AR101901A1 - Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod - Google Patents
Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimodInfo
- Publication number
- AR101901A1 AR101901A1 ARP150102975A ARP150102975A AR101901A1 AR 101901 A1 AR101901 A1 AR 101901A1 AR P150102975 A ARP150102975 A AR P150102975A AR P150102975 A ARP150102975 A AR P150102975A AR 101901 A1 AR101901 A1 AR 101901A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- fingolimod
- combination
- drugs
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D1/00—Containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material, by deep-drawing operations performed on sheet material
- B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
- B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
- B65D1/0215—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features multilayered
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Mechanical Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Ceramic Engineering (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para tratar a un sujeto que padece una enfermedad neurodegenerativa que comprende la administración periódica de una cantidad de laquinimod y una cantidad de fingolimod, en donde las cantidades son eficaces para tratar al sujeto cuando se administran juntas. Envases y composiciones farmacéuticas que comprenden laquinimod y fingolimod para tratar a un sujeto que padece una enfermedad neurodegenerativa. Composición farmacéutica que comprende laquinimod para usar como una terapia adyuvante o en combinación con fingolimod, y una composición farmacéutica que comprende fingolimod para usar como una terapia adyuvante o en combinación con laquinimod, para tratar el mencionado sujeto. Reivindicación 51: El método de cualquiera de las reivindicaciones 1 - 50, caracterizado porque además comprende la administración de fármacos antiinflamatorios no esteroides (AINEs), salicilatos, fármacos de acción lenta, compuestos de oro, hidroxicloroquina, sulfasalazina, combinaciones de fármacos de acción lenta, corticosteroides, fármacos citotóxicos, fármacos inmunosupresores y/o anticuerpos. Reivindicación 114: Una composición farmacéutica caracterizada porque comprende una cantidad de laquinimod y una cantidad de fingolimod para usar en el tratamiento de un sujeto que padece una enfermedad neurodegenerativa, en donde el laquinimod y el fingolimod se administran simultáneamente, contemporáneamente o concomitantemente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462050842P | 2014-09-16 | 2014-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101901A1 true AR101901A1 (es) | 2017-01-18 |
Family
ID=55453709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102975A AR101901A1 (es) | 2014-09-16 | 2015-09-16 | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod |
Country Status (5)
Country | Link |
---|---|
US (3) | US20160074380A1 (es) |
EP (1) | EP3193870A4 (es) |
AR (1) | AR101901A1 (es) |
CA (1) | CA2961187A1 (es) |
WO (1) | WO2016044103A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3137092A4 (en) | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
KR102364840B1 (ko) * | 2014-11-05 | 2022-02-18 | 삼성전자주식회사 | 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법 |
WO2017042274A1 (en) * | 2015-09-08 | 2017-03-16 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Quinoline derivates for use in treating leukodystrophy and treatment method |
EP4252748A1 (en) * | 2022-03-31 | 2023-10-04 | Otto-von-Guericke-University Magdeburg | A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia |
WO2024168320A1 (en) * | 2023-02-09 | 2024-08-15 | Anand Rene | Methods and pharmaceutical compositions for treating dementia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE510538T1 (de) * | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
CA2970273C (en) * | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
EP2217561A2 (en) * | 2007-11-02 | 2010-08-18 | Concert Pharmaceuticals, Inc. | Deuterated fingolimod |
EP3064206B1 (en) * | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
CN103781354A (zh) * | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症 |
BR112014008731A2 (pt) * | 2011-10-12 | 2017-04-25 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode |
EP2900330A4 (en) * | 2012-09-27 | 2016-05-25 | Teva Pharma | LAQUINIMOD AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
CA2888634C (en) * | 2012-10-19 | 2019-10-08 | Ruth Perez | Compositions and methods for the treatment of parkinson's disease |
-
2015
- 2015-09-11 EP EP15841386.4A patent/EP3193870A4/en not_active Withdrawn
- 2015-09-11 CA CA2961187A patent/CA2961187A1/en not_active Abandoned
- 2015-09-11 WO PCT/US2015/049799 patent/WO2016044103A1/en active Application Filing
- 2015-09-15 US US14/854,790 patent/US20160074380A1/en not_active Abandoned
- 2015-09-16 AR ARP150102975A patent/AR101901A1/es unknown
-
2017
- 2017-04-21 US US15/493,997 patent/US20170224674A1/en not_active Abandoned
- 2017-08-04 US US15/669,748 patent/US20170354651A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170224674A1 (en) | 2017-08-10 |
US20160074380A1 (en) | 2016-03-17 |
EP3193870A4 (en) | 2018-04-25 |
US20170354651A1 (en) | 2017-12-14 |
EP3193870A1 (en) | 2017-07-26 |
CA2961187A1 (en) | 2016-03-24 |
WO2016044103A1 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
CL2019003091A1 (es) | Terapia de combinación. | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
MX2019003685A (es) | Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. | |
EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |